The RICO Mirage: Why the Second Circuit’s Decongestant Ruling Chokes Off the Treble-Damages Playbook

The Kitchen-Sink Class Action Takes a Hit

For the plaintiffs’ class action bar, the civil Racketeer Influenced and Corrupt Organizations Act (RICO) has long been the ultimate weapon of mass distraction. By dressing up garden-variety consumer fraud allegations as a sprawling criminal conspiracy, plaintiffs can threaten drugmakers and retailers with treble damages and attorneys' fees, hoping to force an early, lucrative settlement. But on July 30, 2026, the Second Circuit Court of Appeals slammed the door on this tactic in the over-the-counter (OTC) pharmaceutical space.

Ruling in a high-stakes false-advertising multidistrict litigation targeting major drugmakers and retailers over decongestant efficacy, the Second Circuit delivered a forceful two-part holding. First, the panel held that federal law preempts most state-law claims challenging "maximum strength" labeling on OTC decongestants. Second, and perhaps more importantly for federal litigators, the court ruled that consumers categorically lack Article III and statutory standing to pursue a civil RICO claim based on these purchases.

While the court technically "partially revived" the litigation—likely leaving a narrow sliver of non-preempted state-law claims to proceed—the decision effectively neuters the plaintiffs' core strategy. By stripping away the RICO threat and dropping the preemption hammer on the primary state consumer-protection claims, the Second Circuit just handed defense counsel a masterclass in how to dismantle a kitchen-sink class action at the pleading stage.

The Preemption Wall: Protecting the FDA Monograph System

To understand why this ruling is a seismic shift for FDA-regulated products, we have to look at the mechanics of federal preemption. Under the Food, Drug, and Cosmetic Act (FDCA), specifically the express preemption provision added by the Food and Drug Administration Modernization Act of 1997, states are prohibited from establishing any requirement for nonprescription drugs that is "different from or in addition to, or that is otherwise not identical with, a requirement under" the FDCA. See 21 U.S.C. § 379r(a).

In the decongestant litigation, plaintiffs argued that labeling products as "maximum strength" violated state consumer protection laws because the drugs were allegedly ineffective. But OTC decongestants are governed by strict FDA monographs—regulatory recipes that dictate permissible active ingredients, dosages, and labeling claims. If a drugmaker complies with the monograph, it is generally shielded from state-law failure-to-warn or false-advertising claims.

The Second Circuit’s ruling reaffirms a fundamental principle of administrative law: plaintiffs cannot use state consumer-protection statutes to second-guess FDA scientific determinations. When federal regulators authorize "maximum strength" language based on established dosing guidelines, state-law claims challenging that exact phrasing are expressly preempted.

For defense attorneys, this ruling is a goldmine. It signals that appellate courts are losing patience with plaintiffs who attempt to end-run the FDA's regulatory authority by pleading their claims under the guise of state deceptive practices acts, such as New York's General Business Law § 349 or California's Unfair Competition Law. Expect to see Rule 12(b)(6) motions heavily citing this Second Circuit decision to knock out "mislabeled" OTC drug claims before discovery even begins.

The Death of the Consumer RICO Shakedown

The most strategically significant aspect of the Second Circuit’s decision, however, is its treatment of civil RICO standing. Under 18 U.S.C. § 1964(c), a civil RICO plaintiff must prove they were injured in their "business or property" by reason of the racketeering activity. The statute was designed to combat organized crime's infiltration of legitimate business, not to provide a federal forum for disappointed shoppers.

Yet, plaintiffs’ lawyers routinely allege that a network of manufacturers, distributors, and retailers forms an "associated-in-fact enterprise" under 18 U.S.C. § 1961(4), conspiring to defraud the public by selling ineffective products. The alleged injury? The "price premium" consumers paid for the drug.

The Second Circuit correctly identified this as a mirage. The court held that the consumers lacked standing to bring a civil RICO claim, reinforcing the strict boundary between economic injury cognizable under RICO and personal injury or standard breach-of-warranty claims. Paying for a decongestant that allegedly doesn't work as well as expected is fundamentally a product-defect or personal-efficacy issue. It does not constitute a concrete, quantifiable injury to "business or property" required to trigger RICO’s draconian treble damages.

Practice Implications: Pivot or Perish

This ruling fundamentally alters the risk calculus for corporate defendants facing false-advertising class actions in the Second Circuit. Here is what practicing litigators need to know:

1. The End of the Settlement Premium: Without the looming threat of RICO's mandatory treble damages and attorneys' fees, the settlement value of these OTC class actions drops precipitously. Defendants can afford to litigate the surviving, non-preempted state-law claims on the merits rather than being blackmailed into early, astronomical settlements.

2. A Roadmap for Early Dismissal: Defense counsel should immediately audit their pending OTC and cosmetics class actions. If plaintiffs are challenging labeling that is explicitly authorized by an FDA monograph or regulation, a motion to dismiss on § 379r express preemption grounds is now practically mandatory.

3. Plaintiffs Will Forum Shop: Because the Second Circuit has drawn a hard line on both preemption and RICO standing in this context, expect the plaintiffs' bar to migrate their filings to more hospitable jurisdictions, perhaps looking to the Ninth or Third Circuits to test different theories of economic injury.

Ultimately, the Second Circuit’s decongestant ruling is a triumph of statutory interpretation over creative pleading. It reminds the class action bar that the FDCA is not a baseline for state-law enhancement, and civil RICO is not a universal remedy for consumer buyer's remorse. For defense litigators, it is the exact appellate ammunition needed to kill these bloated complaints in their infancy.